View:
Nektar
Therapeutics
201
Industrial Road
San
Carlos, California 94070
Sender
Contact Information
P: (650)
620-5990
F: (650)
620-5360
December
18, 2008
VIA FACSIMILE AND U.S.
MAIL
Securities
and Exchange Commission
Division
of Corporate Finance
Washington,
D.C. 20549
Attention: Nandini
Acharya, Esq.
|
|
Re:
|
Nektar Therapeutics.
-- Form 10-K for the Year Ended December 31, 2007 (File No.
000-24006)
|
Dear Ms.
Acharya:
We are in
receipt of the letter dated December 10, 2008 (the “Comment Letter”), including
comments from the staff of the Securities and Exchange Commission to the Form
10-K for the year ended December 31, 2007 (File No. 000-24006) filed by Nektar
Therapeutics, a Delaware corporation, on February 29, 2008.
We will
provide a response to the Comment Letter no later than January 16,
2009.
Please do
not hesitate to call the undersigned at (650) 620-5990 or Jennifer A. DePalma,
Esq. of O’Melveny & Myers LLP, legal counsel to Nektar Therapeutics, at
(650) 473-2670, regarding this matter.
|
Sincerely,
/s/
Gil M. Labrucherie
Gil
M. Labrucherie
Senior
Vice President, General Counsel & Secretary of Nektar
Therapeutics
|
|
cc:
|
Howard W. Robin, President and Chief Executive Officer of Nektar Therapeutics |
|
|
Sam
Zucker, Esq., O’Melveny & Myers
LLP
|
|
|
Jennifer
A. DePalma, Esq., O’Melveny & Myers
LLP
|